Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2012. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details the acquisition of Ordinary Shares on May 10, 2012, at a price of 1407.36 pence per share through the Company's ShareReward Plan. The transactions involved both personal contributions and matching company contributions for the following individuals:
- Sir Andrew Witty: 9 shares (personal) and 9 shares (company match).
- Mr S Dingemans: 9 shares (personal) and 9 shares (company match).
- Mr S M Bicknell: 9 shares (personal) and 9 shares (company match).
- Mr E J Gray: 9 shares (personal) and 9 shares (company match).
- Mr D S Redfern: 9 shares (personal) and 9 shares (company match).
- Ms C Thomas: 9 shares (personal) and 9 shares (company match).
- Mr P C Thomson: 7 shares (personal) and 7 shares (company match).
- Dr P J T Vallance: 9 shares (personal) and 9 shares (company match).
- Mrs V A Whyte: 9 shares (personal) and 9 shares (company match).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director share interests.
Investor Verification Points
- Verify the share price of 1407.36 pence per Ordinary Share on May 10, 2012.
- Confirm the total number of shares acquired by each listed director under the ShareReward Plan.
- Review the company's broader ShareReward Plan terms to understand the matching contribution structure.